期刊文献+

血清MMP-2、VEGF和IL-17在早期非小细胞肺癌诊断价值及相关关系 被引量:10

Diagnostic value of serum MMP-2,VEGF and IL-17 in early non-small cell lung cancer and their correlation
下载PDF
导出
摘要 目的对非小细胞肺癌(NSCLC)患者血清MMP-2、VEGF和IL-17的水平进行检测并分析其相关性。方法以NSCLC患者为研究组,健康体检者为对照组,采用ELISA法,检测研究对象血清MMP-2、VEGF和IL-17水平,并分析其相关性。结果研究组MMP-2、VEGF、IL-17水平均显著高于对照组(P<0.05)。不同性别和不同年龄阶段NSCLC患者血清MMP-2和VEGF水平无明显差异(P>0.05),鳞癌和腺癌患者血清VEGF水平无显著差异(P>0.05),而鳞癌患者血清MMP-2水平显著低于腺癌患者(P<0.05),有淋巴结转移患者MMP-2、VEGF水平均显著高于无淋巴结转移患者(P<0.05),TNM分期为Ⅰ~Ⅱ患者血清MMP-2、VEGF水平显著低于Ⅲ~Ⅳ患者(P<0.05)。不同性别、不同年龄阶段和病理类型NSCLC患者血清IL-17水平无明显差异(P>0.05),有淋巴结转移患者IL-17水平显著高于无淋巴结转移患者(P<0.05),TNM分期为Ⅰ~Ⅱ患者血清IL-17水平显著低于Ⅲ~Ⅳ患者(P<0.05)。NSCLC患者血清MMP-2和IL-17呈正相关关系(r=0.618,P<0.05),VEGF与IL-17呈显著正相关关系(r=0.548,P<0.05)。结论NSCLC患者血清MMP-2、VEGF、IL-17的水平显著升高,且MMP-2、VEGF均与IL-17显著正相关,对NSCLC的早期确诊和治疗有一定的支持作用。 Objective To detect the serum levels of MMP-2,VEGF and IL-17 in patients with non-small cell lung cancer and to analyze their correlations.Methods The patients with non-small cell lung cancer were taken as the study group,and the healthy examiners were taken as the control group.The serum levels of MMP-2,VEGF and IL-17 were detected by ELISA and their correlations were analyzed.Results The levels of MMP-2,VEGF and IL-17 in the study group were significantly higher than those in the control group(P<0.05).There was no significant difference in serum MMP-2 and VEGF levels in NSCLC patients at different genders and at different ages(P>0.05).There was no significant difference in serum VEGF levels in patients with squamous cell carcinoma and adenocarcinoma(P>0.05),while the level of serum MMP-2 in patients with squamous cell carcinoma was significantly lower than that in patients with adenocarcinoma(P<0.05).The levels of MMP-2 and VEGF in patients with lymph node metastasis were significantly higher than those in patients without lymph node metastasis(P<0.05).In TNM staging,the serum levels of MMP-2 and VEGF in patients with Ⅰ~Ⅱ was significantly lower than those in patients with Ⅲ~Ⅳ(P<0.05).There was no significant difference in serum IL-17 levels in NSCLC patients at different genders,different ages and pathological types(P>0.05),and the level of IL-17 in patients with lymph node metastasis was significantly higher than that without lymph node metastasis(P<0.05).In TNM staging,the serum IL-17 level of patients with Ⅰ~Ⅱ was significantly lower than that of patients with Ⅲ~Ⅳ(P<0.05).There was a positive correlation between serum MMP-2 and IL-17 in patients with NSCLC(r=0.618,P<0.05),and a significant positive correlation between VEGF and IL-17(r=0.548,P<0.05).Conclusion The levels of serum MMP-2,VEGF,and IL-17 in NSCLC patients are significantly increased,and MMP-2 and VEGF are significantly positively correlated with IL-17,which can support the early diagnosis and treatment of NSCLC.
作者 任宝恒 袁章安 周庆元 REN Bao-heng;YUAN Zhang-an;ZHOU Qing-yuan(Department of Respiratory and Critical Care Medicine,Affiliated 3201 Hospital of Xi'an Jiaotong University School of Medicine,Hanzhong Shaanxi 723000,China;Department of Respiratory Medicine,Ankang People's Hospital,Ankang,Shaanxi 725000,China)
出处 《临床肺科杂志》 2021年第8期1236-1240,共5页 Journal of Clinical Pulmonary Medicine
关键词 NSCLC MMP-2 VEGF IL-17 诊断 相关性 NSCLC MMP-2 VEGF IL-17 diagnosis correlation
  • 相关文献

参考文献7

二级参考文献88

  • 1Zhu X, Mulcahy LA, Mohammed RA, et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasivenvss of breast cancer cell lines. Breast Cancer Res, 2008, 10(6):R95.
  • 2Saito H, Yamada Y, Takaya S, et al. Clinical relevance of the number of interlenkin-17-producing CD 8+ T cells in patients with gastric cancer. Surgery today, 2015, 45(11):1429-1435.
  • 3Xu CH, Zhan P, Yu LK, et al. Diagnostic value of planral interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions. Tumour Biol, 2014, 35(2):1599-1603.
  • 4He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting tumor sites and myeloid-derived suppressor cells. J lmmunol, 2010, 184(5):2281-2288.
  • 5Benchetrit F, Circe A, Vives V, et al. Interleukin-I 7 inhibits tumor cell growth by means of a T-celllependent mechanism. Blood, 2002, 99(6):2114-2121.
  • 6Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 2009, 31 (5):787-798.
  • 7Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol, 2009, 9(8):556-567.
  • 8Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. J Immunol, 2011, 187(9):4392-4402.
  • 9Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromefie receptor complex. J Immunol, 2006, 177(1):36-39.
  • 10Lee J, I4o WH, Maruoka M, et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rhl. J Binl Chem, 2001, 276(2):1660-1664.

共引文献59

同被引文献114

引证文献10

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部